Next Article in Journal
Enhancing Dissolution and Oral Bioavailability of Ursodeoxycholic Acid with a Spray-Dried pH-Modified Extended Release Formulation
Previous Article in Journal
Development of α-Tocopherol Succinate-Based Nanostructured Lipid Carriers for Delivery of Paclitaxel
Review

Development of New Drugs for Autoimmune Hemolytic Anemia

Division of Hematology, Department of Hematology-Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Lucio Barile
Pharmaceutics 2022, 14(5), 1035; https://doi.org/10.3390/pharmaceutics14051035
Received: 4 April 2022 / Revised: 27 April 2022 / Accepted: 5 May 2022 / Published: 11 May 2022
(This article belongs to the Section Drug Targeting and Design)
Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging. Traditional first-line immunosuppressive therapy, which includes corticosteroids and rituximab, is associated with adverse effects as well as treatment failures, and relapses are common. Subsequent lines of therapy are associated with higher rates of toxicity, and some patients remain refractory to currently available treatments. Novel therapies have become promising for this vulnerable population. In this review, we will discuss the mechanism of action, existing data, and ongoing clinical trials of current novel therapies for AIHA, including B-cell-directed therapy, phagocytosis inhibition, plasma cell-directed therapy, and complement inhibition. View Full-Text
Keywords: autoimmune hemolytic anemia; cold agglutinin disease; warm autoimmune hemolytic anemia; autoimmune hemolytic anemia treatment autoimmune hemolytic anemia; cold agglutinin disease; warm autoimmune hemolytic anemia; autoimmune hemolytic anemia treatment
MDPI and ACS Style

Xiao, Z.; Murakhovskaya, I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022, 14, 1035. https://doi.org/10.3390/pharmaceutics14051035

AMA Style

Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics. 2022; 14(5):1035. https://doi.org/10.3390/pharmaceutics14051035

Chicago/Turabian Style

Xiao, Zhengrui, and Irina Murakhovskaya. 2022. "Development of New Drugs for Autoimmune Hemolytic Anemia" Pharmaceutics 14, no. 5: 1035. https://doi.org/10.3390/pharmaceutics14051035

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop